APG-1387-US-001 (Ascentage Pharma)

Phase 1 Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1387 as a Single Agent or In Combinations with systemic Anti-Cancer Agents in Patients with Advanced Solid Tumors or Hematologic Malignancies